The rumors were right about UnitedHealth Group stock

Rumor that Berkshire would buy UNH proved true.
Berkshire Hathaway purchased 5.04 million shares in Q2.
UNH stock surges 10% on the news after 13F filing.
Support for UNH should readjust back to $300.

Clay Webster FXStreet

After plunging to a five-year low on August 1 at $234.60, the rumor began to circulate that UnitedHealth Group (UNH), the largest private health insurer in the US, might be saved by Warren Buffet's Berkshire Hathaway (BRK-A, BRK-B). While the Oracle of Omaha has opted to retire from his behemoth holding company at the end of the year, it appears he had one large trade still in him.

Berkshire's 13F filing late Thursday shows that it purchased 5.04 million shares of UNH in the second quarter that ended on June 30. The new $1.57 billion position has deteriorated since then, with shares dropping well below its average purchase price of $311.97, but Berkshire has a long history of adding to its positions. Investors will now think that the share price is backstopped by Berkshire's large buying ability.

UNH shares jumped 10.5% in the first few minutes of trading, returning to $300 a share for the first time since July 15.

The Dow Jones Industrial Average (DJIA) has gained 0.5% despite the NASDAQ shedding weight moderately. The market is a bit tepid on Friday after President Donald Trump downplayed Friday's meeting with Russian President Vladimir Putin and US Retail Sales in July arrived in line at 0.5% MoM. Trump is also threatening to institute new tariffs on semiconductor imports.

UnitedHealth Group stock news

UnitedHealth Group is a dividend growth stalwart much in line with Berkshire's history of interest in insurance investments. Investors are not being foolhardy in the hope that Berkshire continues buying while UNH trades at 50% off its all-time high of $630.

Alongside UNH, Berkshire started new positions during Q2 in steelmaker Nucor (NUE) and homebuilder DR Horton (DHI). But neither reached the billion-dollar level of UNH. In order to fund the purchases, Berkshire continued selling shares of Apple (AAPL) and Bank of America (BAC).

While the Justice Department continues to investigate UnitedHealth for alleged Medicare fraud and the insurer deals with higher-than-expected medical cost ratios, the share price will remain subdued overall. But Berkshire's purchase alongside many other hedge funds in Q2 makes the stock look attractive to many bargain hunters.

To make up for those higher medical usage and cost ratios, insurers are asking for an average 15% rise in Affordable Care Act (ACA) exchange plans for 2026, and some insurers have filed for premium hikes of as much as 37%. While these hikes may not be approved, most expect UnitedHealth's business to be on much firmer ground in 2026.

UnitedHealth Group stock forecast

While they wait for the health insurance industry to right the ship, investors can expect UNH to start utilizing the $300 psychological level as a recovered support level. This is where the share price largely held up since UnitedHealth's former CEO, Andrew Witty, resigned in May amid the worrisome cost increase.

Now trading above the 50-day Simple Moving Average (SMA) for the first time since April 16, bulls will target resistance at $342.00 and eventually aim to fill the gap up to $376.84. The worst of the sell-off will be over only when UNH recovers the $438.50 former support level.

UNH daily stock chart

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

GBP/USD extends the drop to 1.3360

GBP/USD builds on Monday’s decline and briefly clinches five-day lows near 1.3360 on Tuesday. Cable’s extra pullback follows the better tone in the Greenback as uncertainty in the Middle East prompts investors to adopt a cautious stance. Meanwhile, an apathetic UK labour market report also collaborates with the selling pressure on the British Pound.

EUR/USD stays offered just above 1.1400

EUR/USD keeps the downtrend well in place for yet another day, challenging the 1.1400 contention zone on Tuesday. The continuation of the selling impulse in spot comes amid decent gains in the US Dollar, which continues to find support in the persistent effervescence surrounding the US-Iran crisis.

Middle East crisis intensifies, Gold up

Gold now seems to have embarked on a consolidative phase below the key $4,100 mark per troy ounce in the latter part of Tuesday’s session. Meanwhile, uncertainty surrounding the Middle East conflict and rising expectations for a hawkish Fed policy outlook are expected to limit the precious metal’s bullish momentum in the near term.

XRP rebounds on rising on-chain activity

Ripple (XRP) ticks up and trades around $1.13 at the time of writing on Tuesday. This rebound aligns with a broader recovery in the cryptocurrency market, attributed to reports that mediators between the United States (US) and Iran are seeking a 10-day cessation of strikes to find a way back to the signed Memorandum of Understanding (MoU).

The Iranian war has again risen

The Iranian war has again risen to the top of the economics factor list. There is no end in sight. Intelligence experts say the current level of offense/retaliation will not change minds in Tehran, while in Washington, Trump fears all-out war, which would mean boots on the ground.

US Dollar mid-year outlook: Exceptional currency, exceptional risks?

The US Dollar enters the second half of 2026 in a markedly different position from a year ago. The King currency has recovered, reflecting persistent US inflation, changing expectations for Fed policy, geopolitical tensions and renewed demand for defensive assets.